All,
It is time to announce the Q1 growth winners from our sales team. As mentioned each of the winners will receive a special prize from me in the coming week or so!
It is all about double digit growth! So that is what this award is all about down to the individual sales representative and directors of sales.
Congratulations to All! If these reps and managers succeed we all succeed! For the Bioness sales team we will begin to include you in the special prizes beginning in Q2.
Exogen and HA Verticals
| Q1 Top 10 Sales Rep Double Digit Growth | |
| Sales Rep | ADS Growth % |
| ROLFO, STEPHANIE | 114.2% |
| AHERN, AMY | 114.1% |
| NAPOLITAN, PHILIP | 72.3% |
| PONZI, MARISSA | 65.3% |
| SEREDINSKI, ELIZABETH | 60.1% |
| BURZINSKI, ALEXANDER | 57.8% |
| ELLIOTT, BARRY | 54.9% |
| TAYLOE, ALEC | 52.5% |
| BLASING, GERALD | 49.3% |
| MCADAM, JARED | 49.2% |
Top Three DOS by Growth
| THAISZ, HEATHER | 21.5% |
| SMITH, RYAN | 21.1% |
| RULON, THOMAS | 20.0% |
Top Three Bone Graft Substitutes Area Managers
| Area Manager | YOY Growth Q1 |
| RIOS, FRANCISCO | 281% |
| STEVENSON, SEAN | 43% |
| SHIRES, NICHOLAS | 36% |
Top Regional Directors Bone Graft Substitutes
| Regional Director | YoY Growth Q1 |
| FRUND, CURT | 55% |
| ST. PIERRE, DAVID | 15% |
International
| Q1 Top 10 Sales Rep Double Digit Growth | |
| DOS Name | ADS Growth % |
| Riley Doyle | 51% |
| Emre Kartoglu | 36% |
| Manuela Ertl | 34% |
| Romana Moreno-Riley | 29% |
| Jack Koopmans | 29% |
| Keven Dupont | 28% |
| Christian Relouw | 26% |
| Klaus Welter | 23% |
| Nikki Stalenhoff | 22% |
| Kelly Marshall | 21% |
We are a growth company that is sustained by keeping and recruiting top talent! Special recognition and congratulations to Shellie Burchett (patient financial services representative) and Tammie Midgett (manager reimbursement services) for winning first and second prize for Q1 talent referrals! Shellie and Tammie are both based in our Memphis office.
Special recognition as well to Mercedes Bayani (VP clinical and regulatory Bioness) and Shanna Hu (senior manager regulatory affairs) for gaining MHLW approval of the L300 Go in Japan 3 months earlier than expected. Special assistant was also provided by Arkady Glukhovsky (VP of R&D Bioness), Jung Kim (director of software engineering Bioness) and Janet Bumbarger (senior manager quality assurance Bioness). The potential of the L300 Go in Japan is significant and we look forward to seeing the “Go” Go in Japan gaining growth and market penetration later this year;)!
Lastly, from everything I have heard the engagement across the Bioness and Bioventus teams on mutual collaboration has been terrific! While there will always be some bumps in the road as you bring two organizations together I want to remind everyone of some key principles we highlighted a couple of weeks ago during the Bioness acquisition announcement that are worth repeating.
- Bioness continues to need to focus on “business as usual” and we look for a strong Q2. The Bioventus team is extremely excited to have you on our team!
- Be patient, we are taking the time to learn about the Bioness organization and for the Bioness team to learn about Bioventus. This mutual understanding will lead to the best decisions relative to integration and efficiencies we can potentially gain.
- We will not perform integration for integration sake with that said communication across the business is paramount to success and this will get easier as we get to know one another and have communication chains strengthened
- We will always work in a transparent and open manner and expect all key managers and leaders to have that consistent mindset
I wish you all a terrific rest of the week and let’s get off to a strong start in Q2!
Best Regards,
Ken